+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Forecast 2024-2030- Product Image
Global Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Forecast 2024-2030- Product Image
Sale

Global Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924893
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023, USD 285.77 billion in 2024, and is expected to grow at a CAGR of 14.89% to reach USD 657.50 billion by 2030.

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics.

However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease.

Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

Market Trends by Segment

  • Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
  • Route of Administration: Growing usage of intravenous administration of antibody therapeutics
  • Source: Increasing use of human antibodies due to its biocompatible nature
  • Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
  • End User: Evolving usage of antibody therapeutics in hospitals

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

SystImmune entered into a pivotal license and collaboration agreement with Bristol Myers Squibb that focuses on the co-development and commercialization of the innovative BL-B01D1, an EGFRxHER3 bispecific antibody-drug conjugate (ADC) that is promising as a first-in-class therapy. Currently undergoing a Phase 1 clinical trial targeting non-small cell lung cancer (NSCLC), BL-B01D1 has already exhibited significant anti-tumor activity and a well-managed safety profile across various solid tumors.

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

AbbVie Inc. partnered with BigHat Biosciences to drive the creation of cutting-edge therapeutic antibodies for oncology and neuroscience. This collaboration aims to streamline the discovery and optimization of superior antibodies for several key therapeutic targets. This initiative reflects the company's dedication to integrating AI and ML advancements into the drug development workflow to expedite the delivery of effective treatments.

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

AbbVie announced the acquisition of ImmunoGen, a significant development that includes control of rights of ELAHERE (mirvetuximab soravtansine-gynx), ImmunoGen's premier cancer therapy. This acquisition is a testament to AbbVie's commitment to expanding its solid tumor treatment capabilities, positioning it to better address the complexities of cancer care.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc.

This research report offers invaluable insights into various crucial aspects of the Antibody Therapeutics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of various cancers and infectious diseases
5.1.1.2. Increasing number of drug discovery activities worldwide
5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
5.1.2. Restraints
5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
5.1.3. Opportunities
5.1.3.1. Advancements in the clinical development of antibody therapeutics
5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
5.1.4. Challenges
5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
5.2. Market Segmentation Analysis
5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
5.3. Market Trend Analysis
5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Antibody Therapeutics Market, by Format
6.1. Introduction
6.2. Antibody Fragment
6.3. Bispecific Antibody
6.4. Monoclonal Antibody
6.5. Polyclonal Antibody
7. Antibody Therapeutics Market, by Route of Administration
7.1. Introduction
7.2. Intravenous
7.3. Subcutaneous
8. Antibody Therapeutics Market, by Source
8.1. Introduction
8.2. Chimeric
8.3. Human
8.4. Humanized
9. Antibody Therapeutics Market, by Disease Areas
9.1. Introduction
9.2. Autoimmune & Inflammatory Diseases
9.3. Hematology
9.4. Immunology
9.5. Neurology
9.6. Oncology
9.7. Osteology
10. Antibody Therapeutics Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Long-term Care Facilities
11. Americas Antibody Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antibody Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antibody Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
14.3.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
14.3.3. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
14.3.4. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
14.3.5. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
14.3.6. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
14.3.7. Japan Grants Patent for Bioarctic’s Parkinson’s Disease Antibody
14.3.8. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
14.3.9. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
14.3.10. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
14.3.11. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
14.3.12. Merck to Develop mAb Through USD 10.8 Billion Acquisition
14.3.13. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 83. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 84. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 85. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 86. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 87. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 88. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 89. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 90. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 91. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 92. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 93. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 94. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 95. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 96. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 97. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 98. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 99. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 100. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 101. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 102. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 137. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 138. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 139. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 140. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 141. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 142. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 143. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 144. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 145. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 146. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 147. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 148. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 149. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 150. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 151. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 152. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 153. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 154. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 155. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 156. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 165. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 166. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 167. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 168. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 169. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 171. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 172. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 173. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 174. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 175. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 176. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 185. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 186. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 195. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 196. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 205. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 206. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 215. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 216. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 225. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 226. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 227. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 228. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 229. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 230. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 231. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 232. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 233. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 234. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 235. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 236. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 245. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 246. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 259. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 260. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 261. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 262. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 263. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 264. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 265. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 266. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 267. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 268. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 269. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 270. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 271. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 272. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 273. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 274. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 275. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 276. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 277. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 278. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 279. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 280. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 281. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 282. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 283. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 284. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 285. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 286. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 287. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 288. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 289. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 290. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 291. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 292. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 293. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 294. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 295. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 296. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 297. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 298. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 299. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 300. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 301. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 302. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 303. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 304. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 305. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 306. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 307. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 308. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 309. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 310. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 311. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 312. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 313. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 314. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 317. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 318. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 319. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 320. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 321. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 322. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 323. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 324. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 325. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 326. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 327. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 328. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 329. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 330. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 331. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 332. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 333. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 334. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 335. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
TABLE 336. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
TABLE 337. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 338. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 339. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
TABLE 340. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
TABLE 341. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 342. NIGERIA ANTIBODY TH

Companies Mentioned

  • AbbVie Inc.
  • AbCellera Biologics Inc.
  • Adaptimmune Therapeutics PLC
  • ADC Therapeutics SA
  • Aenova Holding GmbH
  • Almac Group Limited
  • Amgen Inc.
  • Antikor Biopharma
  • Argenx SE
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • DH Life Sciences, LLC
  • DotBio Pte. Ltd.
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.,
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Incyte Corporation
  • iTeos Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Merus N.V.
  • MoonLake Immunotherapeutics AG
  • MorphoSys AG
  • Novartis AG
  • Novo Nordisk A/S
  • Numab Therapeutics AG
  • Pfizer Inc.
  • PharmAbcine Inc.
  • Pyxis Oncology, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • SAB Biotherapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • TRIO Pharmaceuticals Inc.
  • UCB S.A.
  • Xencor, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 285.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 657.5 Billion
Compound Annual Growth Rate14.8%
Regions CoveredGlobal
No. of Companies Mentioned50

Related Topics

Related Reports

Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Indication (Cancer, CNS Conditions), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Indication (Cancer, CNS Conditions), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 175 Pages
  • Global
From
Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030 - Product Image

Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030

  • Report
  • 198 Pages
  • Global
From
Global Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) and Region - Forecast to 2028 - Product Image

Global Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) and Region - Forecast to 2028

  • Report
  • 307 Pages
  • Global
From
Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030 - Product Image

Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From
Global Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029 - Product Image

Global Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029

  • Report
  • 351 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.